Literature DB >> 34185894

The European Medicines Agency Experience With Pediatric Dose Selection.

Efthymios Manolis1,2, Flora T Musuamba2,3, Kristin E Karlsson2,4.   

Abstract

Getting the right dose regimen for children and adolescents is important but poses great scientific, practical, and ethical challenges. At the same time, the availability of data in adults is a huge advantage and needs to be used optimally when designing studies in children and analyzing pediatric data. Furthermore, the processes of maturation and growth are always key when selecting doses for children. All the above make study adaptations and model-informed approaches imperative for dose exposure-response characterization and dose selection in children. This article summarizes the experience gained in the European Medicines Agency on this topic and proposes some general guiding principles for defining objectives, study designs, and methodology tools for pediatric dose selection.
© 2021, The American College of Clinical Pharmacology.

Entities:  

Keywords:  MIDD (model-informed drug development); exposure response; modeling and simulation; pediatrics (PED); regulatory/scientific affairs (REG)

Mesh:

Substances:

Year:  2021        PMID: 34185894     DOI: 10.1002/jcph.1863

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  1 in total

Review 1.  Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.

Authors:  Wen Lin; Yuan Chen; Jashvant D Unadkat; Xinyuan Zhang; Di Wu; Tycho Heimbach
Journal:  Pharm Res       Date:  2022-05-13       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.